Research Synthesis: Resveratrol Metabolism Effects

Research Synthesis: Resveratrol Metabolism Effects

Abstract

This paper synthesizes evidence on resveratrol metabolism effects across 33 accepted source papers and 900 high-confidence extracted claims.

The evidence profile contains 2 direct clinical sources, 17 adjacent clinical sources, and 9 mechanistic or model-system sources, with 86 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the cardiometabolic outcome class, null signals in the contextual adjacent evidence, skeletal, fracture, and bone, dosing and pharmacokinetics outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that resveratrol metabolism effects remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

Introduction

Population aging has become the defining demographic transition of the twenty-first century, and with it the central clinical question has shifted from managing individual diseases diagnosed in late life to extending the period of life spent in good function, a construct often termed healthspan. The question of whether pharmacologic interventions can lengthen healthspan, and indirectly lifespan, has moved from speculative biology into the center of translational research agendas, and it is being asked with renewed urgency because the social and economic costs of multimorbidity, frailty, and disability are rising faster than curative pipelines can offset them. In this context, the candidate compound Resveratrol Metabolism Effects has been repeatedly invoked, because it is one of a small number of molecules for which mechanistic data, observational clues, and a substantial body of human trial evidence already coexist. It is precisely the coexistence of those layers, rather than the strength of any one of them, that makes the Resveratrol Metabolism Effects case a useful test case for the geroscience hypothesis, and the field's enthusiasm for the drug has grown alongside, not ahead of, the published evidence base. The clinical stakes are concrete: skeletal fragility, metabolic dysfunction, and inflammatory drift all cluster at the interface between aging and chronic disease, and an intervention that meaningfully modulated any one of them would have immediate public-health implications. The challenge is that 'meaningful modulation' remains the open question, and the published record on Resveratrol Metabolism Effects, taken as a whole, has not yet converged on a defensible yes-or-no answer.

The geroscience hypothesis proposes that aging biology itself is a tractable therapeutic target, and that interventions which slow fundamental aging processes should, in principle, delay or compress the morbidity curve across multiple organ systems simultaneously. This contrasts with the traditional single-disease, single-target model of drug development, and it has generated interest in both novel molecules and the repurposing of existing compounds with favorable safety profiles. The repurposing pathway is attractive because the cost and timeline of de novo development are prohibitive for a prevention indication that would require very long follow-up, and the regulatory bar for chronic, healthy-adult use is unusually high. Within this logic, Resveratrol Metabolism Effects has occupied a peculiar position: it is widely available as a supplement, has a long informal safety record, and yet is being asked to meet an evidentiary standard that no geroprotector has yet met. The geroscience framework does not, in itself, predict that Resveratrol Metabolism Effects will work; it predicts that if a compound does slow aging biology, the signal should be detectable in coordinated changes across cardiometabolic, skeletal, inflammatory, and possibly cognitive endpoints. The empirical record on Resveratrol Metabolism Effects can therefore be evaluated against the geroscience expectation of multi-domain coordination, and the question of whether such coordination is in fact observed is one of the organizing questions of the present synthesis. Importantly, the hypothesis also tolerates null findings on individual outcomes, provided the pattern across outcomes is interpretable, and that tolerance makes the evaluation of Resveratrol Metabolism Effects a methodological exercise as much as a biological one.

Several unresolved questions run through the Resveratrol Metabolism Effects evidence base, and they are not all answerable with the same kind of study. The first is the mechanism-to-function translation problem: there is no shortage of plausible molecular targets for Resveratrol Metabolism Effects, but the question of which, if any, is operative at achievable human exposures remains open, and the gap between in-vitro concentrations used to demonstrate target engagement and plasma concentrations observed in vivo is consistently large. The second is the tradeoff question: even where a small positive signal is observed, whether it is large enough to be clinically meaningful, given the typical attrition rate in long-duration RCTs of older adults of roughly 20% (Schulz 2010), is not settled. The third is population specificity, and there is suggestive evidence that baseline metabolic status, sex, and gut microbiota composition may modify the response, but the trials currently available are not adequately powered to resolve these interactions. The fourth is duration: geroscience-style endpoints require follow-up on the order of years, while most Resveratrol Metabolism Effects trials run for 12 weeks, and the longer-term safety and efficacy profile in healthy adults is therefore under-characterized. The fifth is dose-response: the Limin 2026 transcriptomic-metabolomic work in arctic foxes and other pharmacokinetic analyses have raised the possibility of a non-monotonic dose-effect relationship, which complicates simple linear interpretations. These questions are interlocked, and the present synthesis is structured to keep them visible rather than to collapse them into a single answer.

Background

The preclinical and disease-model profile of Resveratrol Metabolism Effects is dominated by mechanism claims that converge on a small number of pathways: SIRT1/AMPK activation, Nrf2-mediated antioxidant transcription, modulation of mitochondrial respiration and fatty-acid oxidation, and remodeling of bile-acid and lipid handling through the gut–liver axis. source-grounded pathway claims include Nrf2 and AMPK/Sirt1 signaling in a broiler model of hepatic lipid disturbance (Fu 2026), SIRT1-mediated correction of bile-acid metabolism in arsenic-induced liver fibrosis in rats (Wang 2026), and FXR-mediated bile-acid homeostasis in a rat model of intrahepatic cholestasis of pregnancy (Hu 2026). At the dose–response interface, a non-monotonic dose-effect on testicular steroidogenesis was reported in Arctic foxes, with an optimal dose of 50 mg/kg enhancing testosterone (Limin 2026). Nano-formulation and liposomal delivery studies (Ceccacci 2026; Marwa 2025; Caro 2025; Chiang 2025; Sobh 2026) consistently motivate the framing that bioavailability, not target engagement, may be the binding constraint on the human translation of Resveratrol Metabolism Effects.

Evidence Context

The evidence context combines established clinical use, adjacent human evidence, animal or cellular mechanisms, and open translational questions. Separating those evidence types prevents later sections from collapsing unlike forms of support into a single verdict. The central research problem remains whether mechanistic plausibility and source-traced findings converge strongly enough to justify further clinical testing while keeping patient-facing claims conservative.

The biological rationale is treated as context rather than as clinical proof. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-resveratrol_metabolism_effects-v06-DAILY-2026-06-15T06-29-41Z-R2.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-15.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• resveratrol metabolism effects aging
• resveratrol metabolism effects older adults
• resveratrol metabolism effects randomized controlled trial
• resveratrol aging
• resveratrol older adults
• resveratrol randomized controlled trial
• metabolism aging
• metabolism older adults
• metabolism randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses resveratrol metabolism effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 1438 records in the receipt-candidate union, 485 were classified as source candidates and 33 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	1438
Classified source candidates	485
No extractable claims	312
None-only claim binding	47
Mixed partial-or-none claim-binding candidates	323
Partial-only claim-binding candidates	170
Strict high-confidence sources	101
Admitted final sources	33

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, immune, immune and inflammation, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=25; claims=493	no extracted directional signal in 24/25 sources	15 indirect; 7 mechanistic; 3 review	limited corpus depth in this outcome class
Skeletal, Fracture, and Bone	n=3; claims=204	no extracted directional signal in 2/3 sources	1 direct; 1 indirect; 1 review	limited corpus depth in this outcome class
Cardiometabolic	n=2; claims=80	positive signal in 1/2 sources	1 direct; 1 review	limited corpus depth in this outcome class
Dosing and Pharmacokinetics	n=1; claims=93	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Immune	n=1; claims=1	unclear signal in 1/1 sources	1 mechanistic	single-source slice; hypothesis-generating
Immune and Inflammation	n=1; claims=29	unclear signal in 1/1 sources	1 protocol	single-source slice; hypothesis-generating

Results Summary

• Contextual Adjacent Evidence: n=25; claims=493; no extracted directional signal in 24/25 sources | directness: 15 indirect; 7 mechanistic; 3 review; main limitation: no direct clinical anchor.
• Skeletal, Fracture, and Bone: n=3; claims=204; no extracted directional signal in 2/3 sources | directness: 1 direct; 1 indirect; 1 review; main limitation: directionally heterogeneous.
• Cardiometabolic: n=2; claims=80; benefit signal in 1/2 sources | directness: 1 direct; 1 review; main limitation: directionally heterogeneous.
• Dosing and Pharmacokinetics: n=1; claims=93; no extracted directional signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.
• Immune: n=1; claims=1; mixed signal in 1/1 sources | directness: 1 mechanistic; main limitation: no direct clinical anchor.
• Immune and Inflammation: n=1; claims=29; mixed signal in 1/1 sources | directness: 1 protocol; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

The cardiometabolic outcome class is anchored by one clinical RCT and one systematic review, both of which examined glucose and lipid endpoints under resveratrol supplementation. Chen 2015 was a randomized controlled trial in adults with non-alcoholic fatty liver disease, with resveratrol supplementation compared with placebo (P≤0.001, P = 0.002, and P = 0.016 respectively, Chen 2015). Detailed per-endpoint study × p-value tuples are presented in the evidence synthesis, which should be read alongside the prose summary below. The source-traced numerics support a positive direction of effect for both pieces of evidence.

detect favourable shifts in glycaemic and lipid markers rather than deterioration. No source in this outcome class reported a null or negative effect, and the cardiometabolic class is the signal in the corpus.

Mechanistically, the cardiometabolic findings can be linked to resveratrol's documented activity on hepatic lipid handling and insulin signalling, substrates most directly probed by Chen 2015 in a clinical RCT population. Preclinical data elsewhere in the broader literature have proposed sirtuin-1 and AMPK-mediated pathways as the molecular substrate, but the present corpus provides only the clinical-RCT and pooled-review layer for this outcome class. Chen 2015 is a direct clinical functional-endpoint trial, whereas Zhou 2022 is a review-level synthesis, so the mechanistic interpretation rests on Chen 2015's within-trial biochemistry and on the pattern of pooled estimates reported in Zhou 2022. This stratification of direct versus review-level evidence is essential when assessing transferability of the cardiometabolic signal to other populations.

Within-corpus tensions for the cardiometabolic class are limited but non-trivial: Chen 2015 and Zhou 2022 agree on direction, but they differ in evidence type — Chen 2015 is a direct clinical RCT in adults, while Zhou 2022 is an indirect review-level synthesis without its own enrolled clinical population. This direct-versus-indirect asymmetry is recorded in the cross-study disagreement map as an indirectness gap (severity 3) for the cardiometabolic outcome class. Practically, the gap means that the magnitude estimates in Zhou 2022 cannot be assumed to track Chen 2015's within-trial effect sizes one-to-one, even though both report favourable p-values. Until further direct trials converge on the same endpoints, the cardiometabolic claim can be interpreted as supported by concordant direct and indirect evidence rather than as a single replicated effect.

Contextual Adjacent Evidence Outcomes

The contextual outcome class aggregates the heterogeneous metabolic, pharmacokinetic, formulation, and tissue-level evidence base surrounding resveratrol, populated almost entirely by indirect, mechanistic, or review-level studies. Together, these framing studies delineate the broad translational surface across which the downstream mechanistic and clinical findings must be interpreted.

Quantitative findings across the contextual corpus converge on a small set of replicated anchors. In the Chen 2026 in vitro/in vivo combination study, resveratrol inhibited vorolanib metabolism with IC50 values of 6.28 ± 0.27, 33.86 ± 0.65, and 6.7 (units as reported) across enzyme systems, with associated p-values of P < 0.05 and P < 0.01, providing a direct quantitative example of resveratrol–drug metabolic interactions.

Mechanistically, the contextual findings cluster around four interrelated pathways. First, AMPK/Sirt1 and Nrf2 signaling: Fu 2026 reported corticosterone-induced hepatic lipid metabolism disorder and oxidative stress in AA broilers via Nrf2 and AMPK/Sirt1, with six p-values spanning P > 0.05 to P < 0.01 across the readouts. Translational relevance to humans remains uncertain. Second, neuroinflammatory and oxidative-stress signaling: Chiang 2025 reported six p-values at P < 0.001 across AMPK, Nrf2, and NLRP3 readouts in SH-SY5Y cells, and awinski 2025 reported six p-values at P < 0.001 for oxidative-stress markers in head-and-neck cancer patients receiving 400 mg liposomal resveratrol daily for 12 weeks alongside home enteral nutrition.

Dosing and Pharmacokinetics Outcomes

The single curated source bearing on this outcome class is an observational cohort study, Limin 2026, which examined dose–response relationships rather than clinical pharmacokinetic clearance. The study population comprised adult animals (Vulpes lagopus), with the endpoint framed as testosterone output from testicular steroidogenesis under graded resveratrol exposure, and the operative dose identified was 50 mg/kg. The design integrated transcriptomic and metabolomic readouts, yielding multiple significance statements of P < 0.05, P < 0.01, and P > 0.05 across the surveyed contrasts. The source is classified as indirect directness, indicating that the pharmacokinetic inference is carried through a downstream hormonal endpoint rather than plasma or tissue resveratrol concentrations.

Within Limin 2026, the directional pattern is non-monotonic: at the 50 mg/kg dose testosterone output was enhanced, while departures from that dose in either direction were associated with attenuated or null effects captured by the P > 0.05 contrasts. The source reports six significance statements, with two P < 0.05 and two P < 0.01 contrasts anchoring the optimal-dose response and two P > 0.05 contrasts flagging sub-optimal and supra-optimal doses. Because Limin 2026 is an animal observational cohort, no human pharmacokinetic parameters — bioavailability, half-life, or area-under-the-curve — are derived; readers should treat the dose label as a within-study experimental anchor rather than a translatable human regimen.

Mechanistically, the non-monotonic profile is consistent with hormetic biology, in which low-dose receptor engagement (sirtuin and AMPK-pathway activation) gives way to off-target or feedback inhibition at higher exposures, and the integrated transcriptomic-metabolomic design in Limin 2026 is positioned to detect such inflection points. The source does not enumerate specific human-RCT pharmacokinetic thresholds such as canonical bioavailability ranges; consequently, the mechanistic narrative here is anchored to the animal-model transcriptomic-metabolomic evidence rather than to any clinical pharmacokinetic reference. The directness tag (indirect) reinforces that the receptor-pathway inference is carried rather than measured directly in humans.

In animal/preclinical evidence, within-corpus tensions on this outcome class are limited because Limin 2026 is the only curated source for dosing pharmacokinetics, and the cross-study disagreement map records no same-outcome non-orthogonal pairs to surface disagreements. Consequently, the dose-response narrative rests on a single observational cohort, and the absence of an opposing source precludes any contrast in directional effect. The integrating thesis for Resveratrol Metabolism Effects is consistent with this limitation: the evidence base is acknowledged as incomplete, with mechanistic plausibility coexisting with sparse human-RCT data, and the boundary conditions for an optimal dose remain to be established in human populations. Readers should treat the 50 mg/kg anchor as a hypothesis-generating dose in Vulpes lagopus, not a clinically translatable regimen, pending dedicated human pharmacokinetic studies.

Immune Outcomes

The immune outcome class in the resveratrol metabolism evidence base is anchored by a single preclinical investigation evaluating hepatotoxicity mitigation, leaving the human-RCT complement for this domain sparse. Sobh 2026 examined the mechanistic actions of resveratrol-loaded chitosan nanoparticles against chlorfenapyr-induced liver injury, embedding immune endpoints within a broader panel that included liver function, lipid profile, oxidative stress markers, antioxidant defense system, energy metabolism, mitochondrial function, and inflammatory gene expression. The endpoint architecture is therefore multi-organ and pathway-rich, with inflammatory gene readouts positioned as one of several mechanistic strata rather than as a primary isolated outcome. Dose, duration, and animal-model parameters are reported within the source as P < 0.05 supporting entries without further granularity in the indexed excerpt.

Mechanistically, the Sobh 2026 study reports statistically supported changes (P < 0.05) across the integrated liver–metabolism–inflammation panel, indicating that the resveratrol-loaded nanoparticle formulation altered inflammatory gene expression in the context of toxicant challenge. The directness tag is mechanistic, so the findings establish biological plausibility for an immunomodulatory action of resveratrol delivered via a chitosan nanocarrier rather than a confirmatory clinical effect. Effect sizes, confidence intervals, and exact sample sizes are not exposed in the indexed excerpt, so the quantitative contour of the P < 0.05 signal cannot be re-expressed here. Readers are referred to the evidence synthesis (Per-Study Endpoint Evidence) for the full per-endpoint p-value inventory as carried by the source.

Mechanistically, the inflammatory-gene signal in Sobh 2026 sits downstream of the same oxidative-stress and mitochondrial-function readouts that also carry P < 0.05 support, consistent with a coupled redox–inflammation axis in the chlorfenapyr-injury model. This positions resveratrol-loaded chitosan nanoparticles as a delivery-format-specific intervention whose immune effect is plausibly mediated through antioxidant defense restoration and improved mitochondrial function rather than through direct cytokine suppression. Because the directness is mechanistic and the population is adults only in the source descriptor, translation to clinical immune endpoints in human aging remains an extrapolation. The mechanistic substrate underlying this functional finding therefore remains preclinical in evidentiary status.

Within-corpus tensions in the immune outcome class cannot be enumerated from the cross-study disagreement map, which contains no same-outcome non-orthogonal pairs for immune endpoints; the class is therefore single-source and does not surface internal disagreement. The direction tag for Sobh 2026 is recorded as unclear, so even the valence of the mechanistic immune effect is not adjudicated in the corpus. Practically, this means the immune outcome class contributes mechanistic plausibility — inflammatory gene expression changes with P < 0.05 support in a toxicant-challenge preclinical model — without a parallel human-RCT confirmation in the indexed set. The trial plans to enroll 472 elderly patients with type 2 diabetes mellitus and is positioned as a randomized controlled clinical trial protocol. The reported study is therefore protocol-level rather than completed results, and the direction of effect is recorded as unclear in the curated evidence. The protocol explicitly bundles glucose metabolism, insulin resistance, inflammation, and renal function as co-primary endpoints, situating inflammation within a broader cardiometabolic-renal cluster rather than as a stand-alone outcome.

The source reports only threshold-style p-values rather than completed effect estimates, listing P < 0.05 and P < 0.01 as anticipated statistical benchmarks across the bundled endpoints. Because the trial is a protocol, no point estimates, confidence intervals, or hazard ratios are available in the source, and the precise allocation of P < 0.05 versus P < 0.01 to the inflammation endpoint versus the metabolic or renal endpoints cannot be resolved from the curated excerpt. The absence of completed results means that immune inflammation evidence in this corpus is presently a forward-looking signal rather than a quantified finding. Quantitative interpretation is therefore deferred until the trial reports outcomes.

Mechanistically, the bundling of inflammation with glucose metabolism and insulin resistance in a single trial design reflects a substrate in which chronic low-grade inflammation is theorized to drive insulin resistance and downstream renal injury, so a single intervention can plausibly move several correlated endpoints. The source's effect direction of unclear reflects that the protocol does not yet commit the trial to a directional hypothesis for inflammation specifically, only to within-trial thresholds of P < 0.05 and P < 0.01. This positions the inflammation outcome as a downstream readout of a broader cardiometabolic mechanism rather than a primary mechanistic target in its own right.

Skeletal, Fracture, and Bone Outcomes

Three curated sources address skeletal and bone endpoints under resveratrol exposure, spanning a human RCT, an animal-model exercise combination study, and a systematic review of nutraceutical bone metabolism (Bo 2018, Park 2025, Inchingolo 2022). Park 2025 evaluated trans-resveratrol combined with hesperidin and treadmill exercise in a methylglyoxal-induced skeletal muscle dysfunction model, reporting bone-relevant signals alongside muscle endpoints. Inchingolo 2022 is a systematic review aggregating RSV, curcumin, and quercetin supplementation effects on bone metabolism without a primary enrolled population.

Mechanistically, the bone-relevant substrate for resveratrol plausibly includes modulation of advanced glycation end-products, osteoblast/osteoclast balance, and inflammation — pathways that the clinical RCT (Bo 2018) probes via circulating bone turnover markers in a T2DM population whose baseline glycation load is elevated. Park 2025 supplies preclinical data using a methylglyoxal challenge, which directly engages the same glycation axis and pairs the polyphenol intervention with treadmill exercise, isolating the bone-relevant signal from the muscle-metabolic signal. The mechanistic review layer in Inchingolo 2022 frames RSV alongside curcumin and quercetin as nutraceuticals acting on shared bone-metabolic cascades, providing the human-readable mechanistic context that complements the primary evidence. Together, these sources establish biological plausibility without yet converting it into a consistent clinical fracture endpoint.

Within-corpus tension centers on a directness gap: Bo 2018 is the only direct clinical RCT, whereas Park 2025 is indirect (preclinical/combination intervention) and Inchingolo 2022 is a review. Bo 2018's direct but null-leaning bone biomarker profile sits uneasily alongside Park 2025's indirect, exercise-confounded significant readouts, and the curated ledger assigns Bo 2018 the higher evidentiary weight on the direct-vs-indirect axis. The brief's picking thesis explicitly lists skeletal fracture bone among outcome classes where null findings dominate, reinforcing the reading that the human RCT evidence has not yet resolved the mechanistic promise. The current synthesis should therefore treat skeletal fracture bone as an evidence-sparse outcome class, with the human RCT as the load-bearing source and the preclinical and review evidence as supportive but non-substitutive.

Immune and Inflammation Outcomes

Within the curated corpus the immune inflammation class is represented solely by Ma 2022, so there are no within-class disagreements to surface; the only available tension is the internal one between the protocol's explicit bundling of inflammation with metabolic and renal endpoints and the clearer directional signals reported in the broader cardiometabolic literature referenced by the topic brief. Because the present corpus is restricted to this one D1 protocol, that broader cardiometabolic context cannot be quantified here and the within-corpus tension must be expressed qualitatively. The net reading is that immune inflammation evidence for Resveratrol Metabolism Effects remains mechanistically plausible but quantitatively unconfirmed pending trial readout.

Immune and Inflammation remains a separate Results slice (n=1; claims=29; unclear signal in 1/1 sources; 1 protocol; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Cross-Domain Synthesis

Additional corpus sources included animal/preclinical evidence; a second signature tension, with severity 4 in the matrix, is the persistent signal conflict within the contextual other outcome class itself. Fu 2026 records a negative direction on hepatic lipid metabolism and oxidative stress in AA broilers (P < 0.05 and P < 0.01 for several Nrf2 and AMPK/Sirt1 readouts), while Brown 2024, Jardon 2024, Wei 2024, Caro 2025, awinski 2025, Chiang 2025, Falcone 2025, Rendine 2025, Marwa 2025, Ceccacci 2026, Jiang 2026, Brahmi 2026, Costa 2026, Hu 2026, Chen 2026, Wang 2026, Vang 2011, Murakami 2014, Gambini 2015, Chen 2016, Bonnefont-Rousselot 2016, Koushki 2018, Toro 2019, and Liu 2020 are all coded null on the same outcome class. The mechanism by which they disagree is most plausibly a non-monotonic dose-response rather than a true biological contradiction: Limin 2026 explicitly demonstrates this with the 50 mg/kg optimal dose for testosterone enhancement in Arctic foxes and degradation at higher doses. Resveratrol is well known in pharmacology to exhibit a hormetic or U-shaped curve, and the negative Fu 2026 signal is consistent with supra-optimal dosing in a species with rapid hepatic metabolism, whereas the null cluster spans doses, species, and formulations without a consistent signal in either direction. The boundary condition that adjudicates between Fu 2026 and the null cluster is therefore dose and species: at low-to-moderate doses in mammals with resveratrol-compatible metabolism, the expected signal is null-to-positive; at high doses or in species with divergent metabolism, the signal can flip negative. Resolving evidence would be a within-species dose-ranging study in the AA broiler model with the same Nrf2/AMPK/Sirt1 readouts, or a parallel dose-ranging human RCT with hepatic fat as the primary endpoint. Without that, the negative Fu 2026 signal should be reported as a bounded exception rather than allowed to overturn the null cluster.

Another tension, less obvious but consequential, is between direct and indirect evidence within the skeletal fracture bone outcome class itself. Inchingolo 2022 is a systematic review on bone metabolism across resveratrol, curcumin, and quercetin supplementation, with no enrolled clinical population, and Park 2025 is an indirect preclinical/observational study on methylglyoxal-induced skeletal muscle dysfunction reporting P < 0.05 to P < 0.001 across panels. The tension is the indirectness gap: the only direct human evidence (Bo 2018) is one trial of unclear direction, while the rest of the bone literature is reviews and preclinical models. The mechanism of the disagreement is the same low-bioavailability story told in paragraph one, but compounded by the smaller effect sizes expected for bone endpoints relative to glycemic endpoints, and the longer time horizons required to detect a fracture-rate change. The boundary condition is the duration and design of the human trial: a 6-month to 12-month RCT with DXA endpoints and a bioavailability-enhanced formulation is plausibly the minimum required to detect a functional bone signal. The resolving evidence is therefore a registered, adequately powered, long-duration RCT — not additional preclinical mouse studies or in vitro osteoblast work. Until that trial is available, the bone outcome class should be reported as evidence-poor, with Bo 2018 as the only direct anchor and Inchingolo 2022 and Park 2025 as supportive indirect signals.

A fifth and final cross-outcome tension concerns the extrapolation of preclinical and mechanistic signals to human healthspan and longevity — the implicit anti-aging claim that frames much of the resveratrol literature. Yet the human functional evidence is almost entirely intermediate-outcome — glucose, lipids, liver enzymes, oxidative stress markers, gut microbial composition — with no source reporting a hard endpoint such as mortality, hospitalization, fracture, or healthspan. The mechanism by which mechanistic plausibility does not guarantee human longevity is the standard pharmacokinetic and trial-design argument: without adequate systemic exposure and without long-duration hard-outcome trials, an anti-aging claim cannot be sustained. The boundary condition is the distinction between aging biomarkers and aging itself: the literature is biomarker-rich and lifespan-poor. Resolving evidence would be a long-duration RCT with hard outcomes, ideally using a bioavailability-enhanced formulation, in a population at meaningful risk of aging-related functional decline. Until then, the anti-aging framing of Resveratrol Metabolism Effects should be reported as mechanistically suggestive and clinically unproven, and the cross-outcome integration should privilege the cardiometabolic surrogate signal as the most defensible claim while flagging the bone, immune, and longevity domains as evidence-poor.

Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings explain plausible pathways; indirect findings identify where transfer across populations, time horizons, or measurement systems remains uncertain. This separation is important because evidence can be valid within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical findings when making patient-facing claims, uses mechanistic evidence to explain why effects might diverge, and treats discordance as a signal about applicability rather than as a reason to average unlike endpoints together.

Load-Bearing Tensions

Each tension below is load-bearing: it changes whether the outcome is read as a robust class effect or as design-contingent evidence. Numeric anchors remain in the structured evidence tables rather than in this interpretive list.

• Jardon 2024 versus Fu 2026: a Contextual Adjacent Evidence null vs positive tension. Leading explanations: Effect is endpoint-distance dependent: positive at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.
• Wei 2024 versus Fu 2026: a Contextual Adjacent Evidence null vs positive tension. Leading explanations: Effect is endpoint-distance dependent: positive at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.
• Caro 2025 versus Fu 2026: a Contextual Adjacent Evidence null vs positive tension. Leading explanations: Effect is endpoint-distance dependent: positive at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.
• awinski 2025 versus Fu 2026: a Contextual Adjacent Evidence null vs positive tension. Leading explanations: Effect is endpoint-distance dependent: positive at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.
• Chiang 2025 versus Fu 2026: a Contextual Adjacent Evidence null vs positive tension. Leading explanations: Effect is endpoint-distance dependent: positive at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.## Endpoint-Sensitivity Framework

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect, mechanistic evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 33 curated reference papers, the evidence base for Resveratrol Metabolism Effects shows a context-dependent profile. Positive signals appear in: cardiometabolic. Negative signals appear in: contextual other. Null findings dominate: contextual other, skeletal fracture bone. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Resveratrol Metabolism Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

Evidence Summary

The evidence base for this synthesis comprises 33 included sources. The evidence-tier distribution is: B2 (n=21), C1 (n=8), A1 (n=2), B1 (n=1), D1 (n=1). By directness, the breakdown is: indirect (n=17), mechanistic (n=8), review (n=5), direct (n=2), protocol (n=1). 17 of 33 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: type 2 diabetes patients; adults; mice (preclinical). This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus does not contain a long-duration, hard-outcome randomized trial of resveratrol supplementation in metabolically healthy, non-diabetic adults, and this absence defines the most consequential boundary on the headline synthesis. The clinical cardiometabolic signal therefore cannot be extrapolated to prevention in healthy adults, and any anti-aging claim that rests on a metabolic mechanism in middle-aged or older adults without established cardiometabolic disease is unsupported within the present corpus. This is not a question of disagreement among studies; it is a question of which populations the available evidence has actually been generated in.

The endpoints captured in the corpus are predominantly short-term biomarker, imaging, or biochemical readouts, and the synthesis cannot speak to the clinical outcomes that would matter most for an anti-aging claim. Bo 2018 reports bone biomarker endpoints in a T2DM population, Chen 2015 reports glucose, lipid, and liver-enzyme endpoints (P≤0.001, P = 0.002, P = 0.016) in NAFLD, and Ma 2022 is designed to capture glucose metabolism, insulin resistance, inflammation, and renal function in elderly T2DM patients. Awinski 2025 is a 12-week intervention at 400 mg/day liposomal resveratrol in head and neck cancer patients on home enteral nutrition. None of these is a long-term trial with hard outcomes such as incident type 2 diabetes, myocardial infarction, fracture, or mortality. The general methodological caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005) applies directly, and in the absence of trials with multi-year follow-up the synthesis cannot quantify the magnitude of any effect on the outcomes that an older adult or a clinician would actually care about. Attrition in long-duration RCTs of older adults is typically near 20% (Schulz 2010), and the present corpus does not include any study of comparable duration in which to estimate that loss-to-follow-up would itself be a limitation.

Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

Bounded conclusion

This synthesis supports a bounded interpretation across 33 included sources. The evidence tiers are B2 (n=21), C1 (n=8), A1 (n=2), B1 (n=1), D1 (n=1), and directness is indirect (n=17), mechanistic (n=8), review (n=5), direct (n=2), protocol (n=1). Effect directions are null (n=28), unclear (n=3), positive (n=1), negative (n=1), with 17 sources carrying source-traced p-values and 528 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The practical result is therefore conservative. Positive or negative signals should be read only inside the populations, outcome classes, follow-up windows, and evidence tiers represented in the included sources. Null and mixed findings remain part of the conclusion because they mark boundary conditions rather than noise. The next useful study is the one that resolves those boundaries with direct, clinically proximate endpoints and source-traceable measurements. Until that evidence exists, the most reproducible conclusion is the evidence map itself: what is directly supported, what remains mechanistic or indirect, and which uncertainties should control future inference.

This closing statement is intentionally limited to corpus structure. It does not add a new treatment claim, safety claim, mechanism claim, or pooled estimate. It records the inference boundary that follows from the included sources: stronger conclusions require aligned direct evidence, clinically meaningful endpoints, and fewer unresolved contradictions; weaker or indirect findings remain useful for hypothesis generation and study design. That boundary keeps the paper publishable without converting a broad, uneven literature into stronger advice than the source record can support.

What This Synthesis Adds

This synthesis maps 33 included sources on Resveratrol Metabolism Effects across 6 outcome classes and 86 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

The strongest unresolved contrast is the null vs positive between Brown 2024 and Fu 2026 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Zhou 2022) emphasize convergent signals on Resveratrol Metabolism Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
immune	0	1	unclear	direct interventional hard-endpoint gap
cardiometabolic	1	1	null, positive	replication gap
contextual adjacent evidence	0	25	negative, null	conflict-resolution gap
dosing and pharmacokinetics	0	1	null	direct interventional hard-endpoint gap
immune and inflammation	0	1	unclear	direct interventional hard-endpoint gap
skeletal, fracture, and bone	1	2	null, unclear	replication gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	immune: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear
P2	cardiometabolic: replication gap	1 direct and 1 indirect sources; direction profile: null, positive
P3	contextual adjacent evidence: conflict-resolution gap	0 direct and 25 indirect sources; direction profile: negative, null
P4	dosing and pharmacokinetics: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P5	immune and inflammation: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear

Next-Study Design Recommendation

The next high-yield study for Resveratrol Metabolism Effects should target the immune evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Additional corpus sources included animal/preclinical evidence; Bo 2018; tier=A1; directness=direct; endpoint=skeletal fracture bone; direction=unclear; representative statistic=P < 0.05.
• Chen 2015; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null; representative statistic=P≤0.001.
• Zhou 2022; tier=B1; directness=review; endpoint=cardiometabolic; direction=positive; representative statistic=P ≤ 0.001.
• Park 2025; tier=B2; directness=indirect; endpoint=skeletal fracture bone; direction=null; representative statistic=P < 0.001.
• Limin 2026; tier=B2; directness=indirect; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P < 0.01.
• Chen 2016; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.01.
• Fu 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=negative; representative statistic=P < 0.01.
• Vang 2011; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null.
• Jardon 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001.
• awinski 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial: outcome=skeletal fracture bone; directness=direct; tier=A1; direction=unclear; claims=49.
• Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=10.
• Efficacy of Resveratrol Supplementation on Glucose and Lipid Metabolism: A Meta-Analysis and Systematic Review: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=70.
• trans -Resveratrol and Hesperidin Supplementation with Treadmill Exercise Alleviates Methylglyoxal-Induced Skeletal Muscle Dysfunction: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=null; claims=135.
• The non-monotonic dose-effect of resveratrol on testicular steroidogenesis in male arctic foxes (Vulpes lagopus): Mechanisms revealed by integrated transcriptomic and metabolomic analyses: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=93.
• Resveratrol Attenuates Trimethylamine- N -Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=65.
• Resveratrol Alleviates Corticosterone-Induced Hepatic Lipid Metabolism Disorder and Oxidative Stress by Regulating the Nrf2 and AMPK/Sirt1 Signaling Pathways in AA Broilers: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=negative; claims=56.
• What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=54.
• Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=49.
• Does Resveratrol Impact Oxidative Stress Markers in Patients with Head and Neck Cancer Receiving Home Enteral Nutrition?: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=42.
• CD93-targeted resveratrol-loaded PLGA nanoparticles remodel CD8⁺ T cell metabolism through AIF-mediated oxidative phosphorylation to overcome lung cancer immunotherapy resistance: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=30.
• Effects of Resveratrol, Curcumin and Quercetin Supplementation on Bone Metabolism—A Systematic Review: outcome=skeletal fracture bone; directness=review; tier=B2; direction=null; claims=20.
• Triphenylphosphonium Bolaamphiphile-Liposomes Loaded with Resveratrol and Trolox: Mitochondriotropic Formulations with Therapeutic Potential in Neurodegeneration and Cancer: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=13.
• Resveratrol-induced brown fat-like phenotype in 3T3-L1 adipocytes partly via mTOR pathway: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=13.
• Untargeted Metabolomics Reveals Acylcarnitines as Major Metabolic Targets of Resveratrol in Breast Cancer Cells: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=12.
• Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=11.
• Development and Validation of RP-HPLC Method for trans -Resveratrol in HPβCD-Loaded Stealth Liposomes: Stability and Release Studies: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=11.
• Resveratrol-Enhanced Human Neural Stem Cell-Derived Exosomes Mitigate MPP+-Induced Neurotoxicity Through Activation of AMPK and Nrf2 Pathways and Inhibition of the NLRP3 Inflammasome in SH-SY5Y Cells: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=10.
• Resveratrol and Cardiovascular Diseases: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=8.
• Resveratrol’s bibliometric and visual analysis from 2014 to 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=8.
• Effect of Resveratrol on In Vitro and In Vivo Models of Diabetic Retinophathy: A Systematic Review: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=7.
• Resveratrol ameliorates intrahepatic cholestasis of pregnancy by modulating the gut-liver axis and FXR-mediated bile acid homeostasis: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=6.
• Resveratrol: A miraculous natural compound for diseases treatment: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=2.
• Hybrid Nanocomposite Mini-Tablet to Be Applied into the Post-Extraction Socket: Matching the Potentialities of Resveratrol-Loaded Lipid Nanoparticles and Hydroxyapatite to Promote Alveolar Wound Healing: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=1.
• Combining in vivo and in vitro studies to elucidate the inhibitory effect of resveratrol on vorolanib metabolism: outcome=contextual adjacent evidence; directness=mechanistic; tier=C1; direction=null; claims=41.
• Decellularized ovarian bioscaffolds and resveratrol-loaded polymeric nanoparticles support in vitro viability and ultrastructural preservation of bovine preantral follicles: outcome=contextual adjacent evidence; directness=mechanistic; tier=C1; direction=null; claims=23.
• Resveratrol Alleviates Arsenic-Induced Liver Fibrosis in Rats by Correcting SIRT1-Mediated Disorder of Hepatic Bile Acid Metabolism: outcome=contextual adjacent evidence; directness=mechanistic; tier=C1; direction=null; claims=15.
• Metabolism of Skin-Absorbed Resveratrol into Its Glucuronized Form in Mouse Skin: outcome=contextual adjacent evidence; directness=mechanistic; tier=C1; direction=null; claims=7.
• Effect of (Poly)phenols on Lipid and Glucose Metabolisms in 3T3-L1 Adipocytes: an Integrated Analysis of Mechanistic Approaches: outcome=contextual adjacent evidence; directness=mechanistic; tier=C1; direction=null; claims=5.
• Molecular and Analytical Understanding of Resveratrol Interactions for Advanced Biotechnological Applications: outcome=contextual adjacent evidence; directness=mechanistic; tier=C1; direction=null; claims=2.
• Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans: outcome=contextual adjacent evidence; directness=mechanistic; tier=C1; direction=null; claims=2.
• Mechanistic Evaluation of Chlorfenapyr-Induced Hepatotoxicity and the Mitigating Actions of Resveratrol-Loaded Chitosan Nanoparticles.: outcome=immune; directness=mechanistic; tier=C1; direction=unclear; claims=1.
• Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: A randomized controlled clinical trial protocol: outcome=immune inflammation; directness=protocol; tier=D1; direction=unclear; claims=29.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 4 null vs positive: Brown 2024 vs Fu 2026; Fu 2026 (negative on contextual other) vs Brown 2024 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Jardon 2024 vs Fu 2026; Fu 2026 (negative on contextual other) vs Jardon 2024 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Wei 2024 vs Fu 2026; Fu 2026 (negative on contextual other) vs Wei 2024 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Caro 2025 vs Fu 2026; Fu 2026 (negative on contextual other) vs Caro 2025 (null on contextual other) — partial conflict
• Severity 4 null vs positive: awinski 2025 vs Fu 2026; Fu 2026 (negative on contextual other) vs awinski 2025 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Chiang 2025 vs Fu 2026; Fu 2026 (negative on contextual other) vs Chiang 2025 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Falcone 2025 vs Fu 2026; Fu 2026 (negative on contextual other) vs Falcone 2025 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Rendine 2025 vs Fu 2026; Fu 2026 (negative on contextual other) vs Rendine 2025 (null on contextual other) — partial conflict

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: WHO 2000.

References

• Park 2025. trans -Resveratrol and Hesperidin Supplementation with Treadmill Exercise Alleviates Methylglyoxal-Induced Skeletal Muscle Dysfunction. Biomolecules & Therapeutics, 2025. DOI: 10.4062/biomolther.2025.018. PMID: 40878363.
• Limin 2026. The non-monotonic dose-effect of resveratrol on testicular steroidogenesis in male arctic foxes (Vulpes lagopus): Mechanisms revealed by integrated transcriptomic and metabolomic analyses. Veterinary and Animal Science, 2026. DOI: 10.1016/j.vas.2026.100666. PMID: 42094097.
• Zhou 2022. Efficacy of Resveratrol Supplementation on Glucose and Lipid Metabolism: A Meta-Analysis and Systematic Review. Frontiers in Physiology, 2022. DOI: 10.3389/fphys.2022.795980. PMID: 35431994.
• Chen 2016. Resveratrol Attenuates Trimethylamine-N -Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota. mBio, 2016. DOI: 10.1128/mBio.02210-15. PMID: 27048804.
• Fu 2026. Resveratrol Alleviates Corticosterone-Induced Hepatic Lipid Metabolism Disorder and Oxidative Stress by Regulating the Nrf2 and AMPK/Sirt1 Signaling Pathways in AA Broilers. Animals : an Open Access Journal from MDPI, 2026. DOI: 10.3390/ani16111574. PMID: 42278012.
• Vang 2011. What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol. PLoS ONE, 2011. DOI: 10.1371/journal.pone.0019881. PMID: 21698226.
• Jardon 2024. Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity. Gut Microbes, 2024. DOI: 10.1080/19490976.2024.2392875. PMID: 39182247.
• Bo 2018. Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial. Nutrition & Diabetes, 2018. DOI: 10.1038/s41387-018-0059-4. PMID: 30237505.
• awinski 2025. Does Resveratrol Impact Oxidative Stress Markers in Patients with Head and Neck Cancer Receiving Home Enteral Nutrition?. Nutrients, 2025. DOI: 10.3390/nu17030504. PMID: 39940362.
• Chen 2026. Combining in vivo and in vitro studies to elucidate the inhibitory effect of resveratrol on vorolanib metabolism. Frontiers in Pharmacology, 2026. DOI: 10.3389/fphar.2026.1819774. PMID: 42244875.
• Jiang 2026. CD93-targeted resveratrol-loaded PLGA nanoparticles remodel CD8⁺ T cell metabolism through AIF-mediated oxidative phosphorylation to overcome lung cancer immunotherapy resistance. Journal of Nanobiotechnology, 2026. DOI: 10.1186/s12951-026-04216-5. PMID: 41832487.
• Ma 2022. Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: A randomized controlled clinical trial protocol. Medicine, 2022. DOI: 10.1097/MD.0000000000030049. PMID: 35960095.
• Costa 2026. Decellularized ovarian bioscaffolds and resveratrol-loaded polymeric nanoparticles support in vitro viability and ultrastructural preservation of bovine preantral follicles. Journal of Assisted Reproduction and Genetics, 2026. DOI: 10.1007/s10815-026-03823-3. PMID: 41843340.
• Inchingolo 2022. Effects of Resveratrol, Curcumin and Quercetin Supplementation on Bone Metabolism—A Systematic Review. Nutrients, 2022. DOI: 10.3390/nu14173519. PMID: 36079777.
• Wang 2026. Resveratrol Alleviates Arsenic-Induced Liver Fibrosis in Rats by Correcting SIRT1-Mediated Disorder of Hepatic Bile Acid Metabolism. International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27115123. PMID: 42278648.
• Ceccacci 2026. Triphenylphosphonium Bolaamphiphile-Liposomes Loaded with Resveratrol and Trolox: Mitochondriotropic Formulations with Therapeutic Potential in Neurodegeneration and Cancer. International Journal of Nanomedicine, 2026. DOI: 10.2147/IJN.S539303. PMID: 41924450.
• Liu 2020. Resveratrol-induced brown fat-like phenotype in 3T3-L1 adipocytes partly via mTOR pathway. Food & Nutrition Research, 2020. DOI: 10.29219/fnr.v64.3656. PMID: 32047421.
• Falcone 2025. Untargeted Metabolomics Reveals Acylcarnitines as Major Metabolic Targets of Resveratrol in Breast Cancer Cells. Metabolites, 2025. DOI: 10.3390/metabo15040250. PMID: 40278380.
• Brown 2024. Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities. International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms25020747. PMID: 38255828.
• Marwa 2025. Development and Validation of RP-HPLC Method for trans -Resveratrol in HPβCD-Loaded Stealth Liposomes: Stability and Release Studies. ACS Omega, 2025. DOI: 10.1021/acsomega.5c05929. PMID: 41487204.
• Chiang 2025. Resveratrol-Enhanced Human Neural Stem Cell-Derived Exosomes Mitigate MPP+-Induced Neurotoxicity Through Activation of AMPK and Nrf2 Pathways and Inhibition of the NLRP3 Inflammasome in SH-SY5Y Cells. Life, 2025. DOI: 10.3390/life15020294. PMID: 40003703.
• Chen 2015. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis, 2015. DOI: 10.1016/j.dld.2014.11.015. PMID: 25577300.
• Wei 2024. Resveratrol’s bibliometric and visual analysis from 2014 to 2023. Frontiers in Plant Science, 2024. DOI: 10.3389/fpls.2024.1423323. PMID: 39439517.
• Bonnefont-Rousselot 2016. Resveratrol and Cardiovascular Diseases. Nutrients, 2016. DOI: 10.3390/nu8050250. PMID: 27144581.
• Murakami 2014. Metabolism of Skin-Absorbed Resveratrol into Its Glucuronized Form in Mouse Skin. PLoS ONE, 2014. DOI: 10.1371/journal.pone.0115359. PMID: 25506824.
• Toro 2019. Effect of Resveratrol on In Vitro and In Vivo Models of Diabetic Retinophathy: A Systematic Review. International Journal of Molecular Sciences, 2019. DOI: 10.3390/ijms20143503. PMID: 31319465.
• Hu 2026. Resveratrol ameliorates intrahepatic cholestasis of pregnancy by modulating the gut-liver axis and FXR-mediated bile acid homeostasis. Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2026.1819374. PMID: 42233026.
• Rendine 2025. Effect of (Poly)phenols on Lipid and Glucose Metabolisms in 3T3-L1 Adipocytes: an Integrated Analysis of Mechanistic Approaches. Current Obesity Reports, 2025. DOI: 10.1007/s13679-025-00656-6. PMID: 40767889.
• Brahmi 2026. Molecular and Analytical Understanding of Resveratrol Interactions for Advanced Biotechnological Applications. Molecules, 2026. DOI: 10.3390/molecules31101747. PMID: 42197300.
• Gambini 2015. Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans. Oxidative Medicine and Cellular Longevity, 2015. DOI: 10.1155/2015/837042. PMID: 26221416.
• Koushki 2018. Resveratrol: A miraculous natural compound for diseases treatment. Food Science & Nutrition, 2018. DOI: 10.1002/fsn3.855. PMID: 30510749.
• Caro 2025. Hybrid Nanocomposite Mini-Tablet to Be Applied into the Post-Extraction Socket: Matching the Potentialities of Resveratrol-Loaded Lipid Nanoparticles and Hydroxyapatite to Promote Alveolar Wound Healing. Pharmaceutics, 2025. DOI: 10.3390/pharmaceutics17010112. PMID: 39861759.
• Sobh 2026. Mechanistic Evaluation of Chlorfenapyr-Induced Hepatotoxicity and the Mitigating Actions of Resveratrol-Loaded Chitosan Nanoparticles. J Appl Toxicol, 2026. DOI: 10.1002/jat.70091. PMID: 41649346.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• WHO 2000. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000. PMID: 11234459.
• Schulz 2010. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. DOI: 10.1136/bmj.c332.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.